BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 29092957)

  • 1. Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.
    Wong HL; Yang KC; Shen Y; Zhao EY; Loree JM; Kennecke HF; Kalloger SE; Karasinska JM; Lim HJ; Mungall AJ; Feng X; Davies JM; Schrader K; Zhou C; Karsan A; Jones SJM; Laskin J; Marra MA; Schaeffer DF; Gorski SM; Renouf DJ
    Cold Spring Harb Mol Case Stud; 2018 Feb; 4(1):. PubMed ID: 29092957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
    Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
    Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
    Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
    Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.
    Liu IH; Ford JM; Kunz PL
    Cancer Treat Rev; 2016 Mar; 44():1-9. PubMed ID: 26924193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
    Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
    Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
    Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
    Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetics of Pancreatic Neuroendocrine Tumors.
    Mohindroo C; McAllister F; De Jesus-Acosta A
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):1033-1051. PubMed ID: 36154786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated clinicopathological features and gene microarray analysis of pancreatic neuroendocrine tumors.
    Zhou H; Chen Q; Tan W; Qiu Z; Li S; Song Y; Gao S
    Gene; 2017 Aug; 625():72-77. PubMed ID: 28479381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.
    Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E
    Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-431 Promotes Metastasis of Pancreatic Neuroendocrine Tumors by Targeting DAB2 Interacting Protein, a Ras GTPase Activating Protein Tumor Suppressor.
    Zhang T; Choi S; Zhang T; Chen Z; Chi Y; Huang S; Xiang JZ; Du YN
    Am J Pathol; 2020 Mar; 190(3):689-701. PubMed ID: 31953039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex-Based Clinicopathologic and Survival Differences Among Patients with Pancreatic Neuroendocrine Tumors.
    Greenberg JA; Ivanov NA; Egan CE; Lee YJ; Zarnegar R; Fahey TJ; Finnerty BM; Min IM
    J Gastrointest Surg; 2022 Nov; 26(11):2321-2329. PubMed ID: 35915373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations.
    Soczomski P; Jurecka-Lubieniecka B; Krzywon A; Cortez AJ; Zgliczynski S; Rogozik N; Oczko-Wojciechowska M; Pawlaczek A; Bednarczuk T; Jarzab B
    Front Endocrinol (Lausanne); 2021; 12():681013. PubMed ID: 34122352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
    Carr JC; Sherman SK; Wang D; Dahdaleh FS; Bellizzi AM; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S739-S746. PubMed ID: 24114056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular alterations in sporadic pancreatic neuroendocrine microadenomas.
    Hadano A; Hirabayashi K; Yamada M; Kawanishi A; Takanashi Y; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
    Pancreatology; 2016; 16(3):411-5. PubMed ID: 26905832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
    Maxwell JE; Sherman SK; Howe JR
    Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor.
    Quevedo R; Spreafico A; Bruce J; Danesh A; El Ghamrasni S; Giesler A; Hanna Y; Have C; Li T; Yang SYC; Zhang T; Asa SL; Haibe-Kains B; Krzyzanowska M; Smith AC; Singh S; Siu LL; Pugh TJ
    Genome Med; 2020 Apr; 12(1):38. PubMed ID: 32345369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.
    Nilubol N; Yuan Z; Paciotti GF; Tamarkin L; Sanchez C; Gaskins K; Freedman EM; Cao S; Zhao J; Kingston DGI; Libutti SK; Kebebew E
    J Natl Cancer Inst; 2018 Sep; 110(9):1019-1029. PubMed ID: 29481652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.
    Pieterman CRC; de Laat JM; Twisk JWR; van Leeuwaarde RS; de Herder WW; Dreijerink KMA; Hermus ARMM; Dekkers OM; van der Horst-Schrivers ANA; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3795-3805. PubMed ID: 28938468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
    Sallinen V; Haglund C; Seppänen H
    Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.